Kliniske studier for Blodkreft i Colorado
14 studier for Blodkreft søker deltakere på steder i Colorado.
Byer i Colorado
Offisiell studietekst (engelsk)
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- University of Colorado Cancer Center ( Site 0021), Aurora
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Rocky Mountain Regional VA Medical Center, Aurora
- UCHealth University of Colorado Hospital, Aurora
- Penrose-Saint Francis Healthcare, Colorado Springs
- og 15 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
RekruttererObservasjonsstudie
Alder 0 til 38 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06131801Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Colorado Blood Cancer Institute ( Site 2726), Denver
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT04728893Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- CBCI, Colorado Blood Cancer Institute, Denver
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT07648264Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Grand Valley Oncology, Grand Junction
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04242095Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Colorado Blood Cancer Institute, Denver
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT06001788A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Colorado Blood Cancer Institute, Denver
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. aug. 2026 · NCT06823167A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Children's Hospital Colorado, Aurora
- University of Colorado Hospital, Aurora
- Presbyterian St. Luke's/Colorado Blood Cancer Institute, Denver
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
- Childrens Hospital of Colorado, Aurora
RekruttererObservasjonsstudie
Opp til 30 år · Alle kjønn · Oppdatert 18. jun. 2026 · NCT06579469A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
- Children's Hospital Colorado, Aurora
RekruttererFase 3
Alder 2 til 18 · Alle kjønn · Oppdatert 5. mai 2026 · NCT05711667A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 13. mar. 2026 · NCT05735184Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital Colorado, Denver
RekruttererFase 1
Alder 1 til 21 · Alle kjønn · Oppdatert 6. des. 2024 · NCT05476770Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.